EUCTR2015-001703-32-NO进行中（未招募）1 期
Phase III multicentric study evaluating the efficacy and safety of sirolimus in Vascular Anomalies that are refractory to standard care. - VASE
Cliniques Universitaires Saint-Luc (CUSL)0 个研究点目标入组 250 人开始时间: 2019年11月28日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion is limited to children and adults from 1 year* to 70 years ( in Norway).
- •* In Belgium, the Netherlands and France 3 months to 70 years. In Germany 18 to 70 years.
- •-Patients with complex vascular anomalies that are refractory to standard care such as medical treatment, surgical resection and/or sclerotherapy/embolization (ineffective or accompanied by major complications) --ref page 57: Clinical parameters / diagnosis: Given the lack of response to conventional treatment (compression stockings, anti-pain, low molecular weight heparin, sclerotherapy and/ or surgery) (Dompmartin et al Phlebology 2010)
- •-Patients must have adequate bone marrow function: Hemoglobine> 10,0 g/dl, neutrophils >1500/mm³ and platelets > 100.000/mm³
- •Patients must have the following laboratory values:
- •-Total serum bilirubin = 1.5 x ULN (Upper Limit Normal) or totally bilirubin =3 x ULN with direct bilirubin = 1.5 x ULN in patients with well documented Gilbert Syndrome
- •--Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 x ULN (or <5.0 x ULN if hepatic metastases are present)
- •-Serum creatinine = 1.5 x ULN. If the serum creatinine is = 1.5 x ULN, then a 24-hour Creatinine Clearance must be conducted and the result must be = 60 mL/min.
- •-Karnofsky score > 50
- •-Patients have to be able to sign the informed consent
- •- For children, parents or legal relatives have to be able to sign the informed consent
- •-Women in age of reproduction have to be informed that contraceptive methods are mandatory during the study time
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 80
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Any of the following concurrent severe and/or uncontrolled medical conditions, which could compromise participation in the study or interfere with the study results:
- •Impaired cardiac function or clinically significant cardiac diseases, including unstable angina pectoris, ventricular arrhythmia, valvular disease with documented compromise in cardiac function, myocardial infarction within the last 6 months, documented by persistent elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LVEF function, history of documented congestive heart failure (New York Heart Association functional classification III-IV), documented cardiomyopathy, family history of congenital long or short QT, or known history of QT/QTc prolongation of Torsades de Pointes (TdP)
- •-Impairment of Gastro-Intestinal (GI) function or GI disease that may significantly alter the absorption of sirolimus (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea = Grade 2, malabsorption syndrome, or small bowel resection)
- •- Known hypersensitivity to drugs or metabolites from similar classes as study treatment.
- •- Patient has other concurrent severe and /or uncontrolled medical condition that would,in the investigator’s judgment, contraindicated participation in the clinical study (e.g. acute or chronic pancreatitis, liver cirrhosis, active chronic hepatitis, severely impaired lung function with a spirometry = 50% of the normal predicted value and/or O2 saturation = 88% at rest, etc.)
- •-Recent history of primary malignancy = 5 years, including history of non-melanoma skin cancer, but With the exception of carcinoma in situ of cervix.
- •-Immunocompromised patients, including known seropositivity for HIV
- •-Pregnant or lactating women
- •-Prior treatment with PI3K and/or mTOR inhibitors
研究者
相似试验
进行中（未招募）
1 期
Sirolimus efficacy in the treatment of vascular anomaliesEUCTR2015-001703-32-BECliniques Universitaires Saint-Luc (CUSL)250
进行中（未招募）
1 期
Sirolimus efficacy in the treatment of vascular anomaliesComplex vascular anomalies causing debilitating functional and esthetic impairment that are resistant to standard careMedDRA version: 18.1Level: HLTClassification code 10047047Term: Vascular anomalies congenital NECSystem Organ Class: 100000004850EUCTR2015-001703-32-FRCliniques Universitaires Saint-Luc (CUSL)250
进行中（未招募）
1 期
Sirolimus efficacy in the treatment of vascular anomaliesEUCTR2015-001703-32-DECliniques Universitaires Saint-Luc (CUSL)250
招募中
1 期
lcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitislcerative ColitisMedDRA version: 20.0Level: PTClassification code: 10009900Term: Colitis ulcerative Class: 100000004856CTIS2022-501788-41-00Abbvie Deutschland GmbH & Co. KG112
进行中（未招募）
1 期
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Crohn's DiseaseCTIS2023-509618-12-00AbbVie Deutschland GmbH & Co. KG137